YI (42) RDGT (43) GRDN (77) CVS (61) ⌘ Pro Terminal →

PetMed Express Inc. (PETS) — RQD Stock Rating Cockpit

$1.18 -0.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

PetMed Express Inc. (PETS) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $25.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PETS)Realized 20D OHLCV Swing Band: ±8%

RSI-14 MOMENTUMNEUTRAL RANGE

34.130 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.24>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.18H: $4

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 10 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PETS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-35.0% ROIC with 28.1% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (18)

Altman-Z 0.24 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like PETS

✓Established market leader in Consumer Staples with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PETS)

✓Walkthrough of PETS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PETS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.32%▼ DESCENDING CHANNEL

2026-10-30O $1.17H $1.20L $1.17C $1.18VOL 42.3K

RES: $1.50SUP: $1.05SMA50: $1.48SMA200: $2.11

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PETS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PETS Butterfly Map → + Track PETS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -21.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PETS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PETS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PETS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PETS)

Consumer Staples Rank #143 of 146 ⚔️ YI vs PETS Full Matrix →

1. Head-to-Head Consumer Staples Peer Comparison (PETS vs. YI, RDGT, GRDN, CVS)

Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)

Across 146 tracked Consumer Staples securities in the Roarable RQD universe, PetMed Express Inc. (PETS) ranks #143 by composite RQD confidence (26/100, grade E) and #117 by equity capitalization ($25.6M). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PETS at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PETS ACTIVE PetMed Express Inc.	E	26/100	—	28.1%	-35.0%	-0.84%	$25.6M	Benchmark Subject
YI 111 Inc.	D-	42/100	—	5.8%	-20.5%	+0.34%	$26.2M	/yi-vs-pets →
RDGT Ridgetech Inc.	D-	43/100	—	3.6%	—	-2.45%	$3.0M	/rdgt-vs-pets →
GRDN Guardian Pharmacy Services Inc. (Class A)	B+	77/100	52.1x	20.2%	37.7%	+0.30%	$2.56B	/grdn-vs-pets →
CVS CVS Health Corporation	C-	61/100	65.3x	45.0%	2.6%	+0.42%	$115.53B	/cvs-vs-pets →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001040130

In its most recent audited fiscal period (FY2025, filed 2026-03-31), PetMed Express Inc. (PETS) reported GAAP revenue of $179.0M (-21.1% vs. FY2024 revenue of $227.0M , and -34.7% cumulative change since FY2023) , GAAP net income of -$57.3M, operating cash flow of -$28.4M, and free cash flow of -$33.0M (-8256.7% YoY). On the balance sheet, PETS closed FY2025 with $88.0M in total assets against $0 in total debt (Altman Z-Score: 0.24, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$179.0M	-$57.3M	-$28.4M	-$33.0M	$88.0M	—
FY2024 (FY)	2025-03-31	$227.0M	-$6.3M	$4.7M	-$395.0K	$144.8M	—
FY2023 (FY)	2024-03-31	$274.1M	-$7.5M	$4.3M	$4.3M	—	—

3. PETS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.18 (-0.84% 1D, market cap $25.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 146 tracked Consumer Staples issuers, PETS ranks #143 in composite RQD confidence.

How does PETS compare to YI and RDGT in the Consumer Staples sector?

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M) and RDGT (Ridgetech Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PETS?

Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PETS trading relative to its 50-day, 200-day, and 52-week technical levels?

PETS last traded at $1.18 (-0.84% on volume of 12,520 shares), positioning the stock -20.27% below its 50-day simple moving average ($1.48) and -44.08% below its 200-day simple moving average ($2.11). Across its 52-week range of $1.15 to $4.10, PETS sits at the 1.0% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($1.09 to $1.27).

PETS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PETS stock right now?

PetMed Express Inc. (PETS) currently earns a Roarable Rating of E (Strong Sell — SELL) with 26/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is PETS's 12-month price target and RQD AI Jury consensus?

PETS's 12-month base price target is $1.01 (range $0.79 to $4.3), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PETS RQD Cockpit PETS 12M Forecast PETS Earnings & Move PETS Dividends & DRIP PETS Insiders & 13F PETS Whale Options PETS Profit Sankey PETS News & Why